Group 1 - The core point of the news is that AoJing Medical has seen a notable increase in financing activities, with a net buy of 3.8958 million yuan over the last three trading days [1] - On July 31, AoJing Medical had a financing buy amount of 0.14 billion yuan, ranking 1144th in the market, with a financing repayment amount of 0.10 billion yuan [1] - Over the last three trading days (July 29-31), the financing buy amounts were 0.13 billion yuan, 0.11 billion yuan, and 0.14 billion yuan respectively [1] Group 2 - In terms of securities lending, on the same day, there were no shares sold or net sold [2]

7月30日，沪深两融数据显示，奥精医疗获融资买入额0.11亿元，居两市第1239位，当日融资偿还额0.15 亿元，净卖出335.84万元。 最近三个交易日，28日-30日，奥精医疗分别获融资买入0.13亿元、0.13亿元、0.11亿元。 融券方面，当日融券卖出0.00万股，净卖出0.00万股。 来源：金融界 ...

通过天眼查大数据分析，奥精医疗科技股份有限公司共对外投资了8家企业，参与招投标项目130次，知 识产权方面有商标信息48条，专利信息134条，此外企业还拥有行政许可21个。 来源：金融界 资金流向方面，今日主力资金净流出1472.89万元，占比成交额18.82%。其中，超大单净流出321.15万 元、占成交额4.1%，大单净流出1151.74万元、占成交额14.72%，中单净流出流入968.61万元、占成交 额12.38%，小单净流入504.27万元、占成交额6.44%。 奥精医疗最新一期业绩显示，截至2025一季报，公司营业总收入4245.97万元、同比减少10.35%，归属 净利润104.15万元，同比减少84.99%，扣非净利润234.15万元，同比减少168.21%，流动比率18.403、速 动比率16.987、资产负债率8.65%。 天眼查商业履历信息显示，奥精医疗科技股份有限公司，成立于2004年，位于北京市，是一家以从事医 药制造业为主的企业。企业注册资本13555.1584万人民币，实缴资本13555.1584万人民币。公司法定代 表人为胡刚。 金融界消息 截至2025年7月30日收盘，奥精医 ...

7月29日，沪深两融数据显示，奥精医疗获融资买入额0.13亿元，居两市第1162位，当日融资偿还额0.12 亿元，净买入58.76万元。 来源：金融界 最近三个交易日，25日-29日，奥精医疗分别获融资买入0.33亿元、0.13亿元、0.13亿元。 融券方面，当日融券卖出0.00万股，净卖出0.00万股。 ...

Group 1 - The latest stock price of Aojing Medical is 19.76 yuan, an increase of 0.24 yuan from the previous trading day [1] - The stock reached a high of 19.90 yuan and a low of 19.35 yuan during the trading session, with a trading volume of 40,088 hands and a transaction amount of 0.78 billion yuan [1] - Aojing Medical specializes in the research, production, and sales of high-end medical devices, including orthopedic implant materials and neurosurgical products, and holds the qualification of a specialized and innovative enterprise [1] Group 2 - On the day of reporting, the net outflow of main funds for Aojing Medical was 2.6681 million yuan, accounting for 0.1% of the circulating market value [1] - Over the past five trading days, the cumulative net outflow reached 4.8744 million yuan [1]

Core Viewpoint - OssaNova, a product of Aojing Medical, has received registration certification in Vietnam, which is expected to aid the company's expansion into overseas markets, although the specific impact on performance remains uncertain [1][3]. Company Announcements Summary - Aojing Medical has announced that its artificial bone repair material received registration certification from the Vietnamese Ministry of Health, effective from July 16, 2025, with a permanent validity [3]. - The registration number for the product is 2502543ĐKLH/BYT-HTTB, classified as a Class D (high-risk medical device) [3]. - The OssaNova artificial bone repair material is primarily used for bone defect repair in oral or plastic surgery where there are no contraindications for bone grafting, and it has previously received registration in China and Indonesia [3]. - The company has decided to cancel its fundraising account at Industrial Bank due to adjustments in the implementation subject and location of fundraising projects, with the cancellation date set for July 23, 2025 [2][3]. - The termination of the related four-party regulatory agreement has been communicated to the sponsor institution Huatai United and the sponsoring representative [3].

Fundraising Overview - The company raised a total of RMB 547,666,677.62 through the issuance of 33,333,334 shares at a price of RMB 16.43 per share, with a net amount of RMB 500,816,913.05 after deducting issuance costs [1][2] - The funds were verified by an accounting firm and were deposited into a dedicated bank account [1] Fund Management - The company and its subsidiaries have opened dedicated fundraising accounts at various banks to ensure proper management and usage of the raised funds [2] - Agreements have been signed with banks to regulate the management of these funds [2][3] Account Closure - The company has closed a specific fundraising account at Industrial Bank Co., Ltd. due to adjustments in the project implementation [4] - The closure of this account has led to the termination of the corresponding four-party supervision agreement [4]

证券代码：688613 证券简称：奥精医疗 公告编号：2025-039 奥精医疗科技股份有限公司（以下简称"公司"或"本公司"）为规范公 司募集资金的存放、使用与管理，提高资金使用效率和效益，保护投资者权益，根 据《上市公司募集资金监管规则》《上海证券交易所科创板股票上市规则》等法 律法规、规范性文件以及相关规定，本公司及子公司北京奥精医疗器械有限责任 公司、山东奥精生物科技有限公司、潍坊奥精健康科技有限公司、嘉兴奥精生 物科技有限公司在商业银行开设了募集资金专项账户，用于项目实施时的募集 资金存放。 1 截至本公告披露日，公司及上述子公司、华泰联合证券有限责任公司（以 下简称"华泰联合"或"保荐机构"）已与招商银行股份有限公司北京分行、兴 业银行股份有限公司北京中关村支行、华夏银行股份有限公司北京分行分别签订 《募集资金三方监管协议》、《募集资金四方监管协议》。 | 开户银行 | 银行账号 | 账户类别 | 账户状态 | | --- | --- | --- | --- | | 兴业银行股份有限公司北京中关 | 321070100100447453 | 募集资金专户 | 本次注销 | | 村支行 | | | ...

Group 1 - Haitong Development reported a net profit of 86.87 million yuan for the first half of 2025, a year-on-year decrease of 64.14% [1] - Haitong Development achieved an operating income of 1.8 billion yuan, a year-on-year increase of 6.74% [1] - Crystal Integrated expects a net profit increase of 39.04% to 108.55% for the first half of 2025, with projected revenue between 5.07 billion yuan and 5.32 billion yuan [1] Group 2 - Aerospace Universe anticipates a net profit increase of 50.59% for the first half of 2025, with a projected net profit of 34.38 million yuan [2] - Aerospace Universe's net profit excluding non-recurring gains is expected to grow by 94.90% [2] Group 3 - Guodian Power reported a total power generation of 206.03 billion kWh for the first half of 2025, a year-on-year decrease of 3.61% [3] - The company's market-based transaction electricity accounted for 91.84% of the total electricity sold [3] Group 4 - Shanghai Pharmaceuticals announced that its tranexamic acid injection has passed the consistency evaluation for generic drugs [5] - The drug is primarily used for treating various bleeding disorders [5] Group 5 - Sanyou Chemical received approval to issue up to 900 million yuan in technology innovation corporate bonds [7] - The bond issuance is valid for 24 months from the date of approval [7] Group 6 - Baiyuntian's BAT4406F injection drug has received approval for clinical trials for additional indications [9] - The drug is a next-generation fully human anti-CD20 antibody [9] Group 7 - Huason Pharmaceutical received three drug re-registration approval notices [10] - The approved drugs include Ganji Bingmei tablets and other formulations [10] Group 8 - Shanying International plans to establish the Zhiyuan Fund with a total scale of 100 million yuan [13] - The fund will primarily invest in product companies related to industrial scenarios [13] Group 9 - Yiqiu Resources announced the sale of two properties in Malaysia for a total of approximately 3.67 million yuan [15] - The sale is part of the company's asset management strategy [15] Group 10 - Guizhou Bailing plans to apply for loans totaling no more than 920 million yuan from multiple banks [16] - The loans will be used to replace maturing loans and supplement working capital [16] Group 11 - Samsung Medical's subsidiary won a transformer procurement contract in Brazil worth approximately 341 million yuan [16] - The contract is part of the company's expansion into international markets [16] Group 12 - Changying Tong expects a net profit increase of 72.12% to 110.33% for the first half of 2025 [17] - The projected revenue is between 173 million yuan and 211 million yuan [17] Group 13 - Canqin Technology anticipates a net profit increase of 50.14% to 61.85% for the first half of 2025 [17] - The expected revenue is between 286 million yuan and 290 million yuan [17] Group 14 - Daya Shengxiang signed a lease agreement with an annual rent of 17 million yuan for a production facility [18] - The lease term is for 3 years and 4 months, including a 4-month rent-free period [18] Group 15 - Zhongzai Zihuan announced the resignation of its general manager due to work adjustments [20] - The company will appoint an interim general manager while searching for a permanent replacement [20] Group 16 - Fuwei Co. received a project notification from a well-known luxury brand for seat development [22] - The total sales amount for the project is expected to reach 4.9 billion yuan [22] Group 17 - Meili Technology's application for convertible bonds has been accepted by the Shenzhen Stock Exchange [26] - The issuance is subject to further approval from regulatory authorities [26] Group 18 - Jinzhik Technology announced a stock suspension due to potential control changes [27] - The suspension is expected to last no more than two trading days [27] Group 19 - Zhongtian Technology plans to distribute a cash dividend of 3 yuan per 10 shares [28] - The dividend distribution date is set for July 25, 2025 [28] Group 20 - Huahai Chengke plans to distribute a cash dividend of 0.2002 yuan per share [30] - The dividend distribution date is set for July 29, 2025 [30] Group 21 - Dasheng Intelligent won a smart transportation project contract worth 122 million yuan [31] - The project involves comprehensive monitoring systems for urban rail transit [31] Group 22 - Dongyue Silicon reported a fire incident affecting production operations [32] - The fire has been controlled, but the extent of damage is still being assessed [32] Group 23 - Shaanxi Guotou A reported a net profit of 726 million yuan for the first half of 2025, a year-on-year increase of 5.74% [35] - The company's operating income decreased by 2.95% [35] Group 24 - Yibo Technology announced a plan to reduce shareholding by up to 3% [37] - The reduction is due to the shareholder's funding needs [37] Group 25 - Xiling Information announced a stock suspension due to potential control changes [39] - The suspension is expected to last no more than two trading days [39] Group 26 - Tianli Lithium Energy plans to reduce shareholding by 4.55% through block trading [40] - The reduction is due to the fund's operational timeline nearing its end [40] Group 27 - Sihui Fushi announced plans for a combined shareholding reduction of up to 3% [42] - The reduction is due to the shareholders' personal funding needs [42] Group 28 - Jinma Leisure announced a plan for a combined shareholding reduction of up to 4.83% [44] - The reduction is due to personal funding needs of the controlling shareholder and executives [44] Group 29 - *ST Zitian's stock may be terminated due to financial reporting issues [46] - The company is under regulatory scrutiny for failing to rectify its financial statements [46]

Group 1: Industry Overview - The oral implant industry in China consists of a comprehensive supply chain, including upstream raw material suppliers, equipment manufacturers, and software developers [1][4] - Upstream suppliers provide materials such as titanium and zirconia, while midstream includes implant manufacturers and distributors, and downstream consists of dental institutions offering implant services [1][4] Group 2: Regional Distribution - The distribution of companies within the oral implant industry is relatively dispersed, with Shandong province having a higher concentration of related enterprises [5] - Key companies in Shandong include Guocera Materials and Zhenghai Bio, while Guangdong has a concentration of upstream suppliers like Aierchuang and Dongfang Zirconium [5] Group 3: Representative Companies - Major companies in the oral implant sector include Tongce Medical, Aojing Medical, and Ruier Group, with varying revenue contributions from their implant services [9][10] - For instance, Yaboshi generated 816 million yuan from implant services, accounting for 51.75% of its total revenue [10] Group 4: Recent Developments - Yaboshi received an A-level rating in a comprehensive evaluation of dental institutions in Suzhou in April 2025 [12] - Tongce Medical acquired 80% of Hangzhou Haiyin Technology for 55.41 million yuan to enhance its dental product design and development capabilities [12] - Aojing Medical showcased its innovative dental products at the International Dental Exhibition in Cologne, Germany, receiving high praise from experts [12]